Navignostics is a company founded in 2022 as a spin-off from the University of Zurich Bodenmiller Lab. Their laboratory and headquarters are located in Horgen, Switzerland, where a growing team of scientists, lab technicians, software developers, and business experts work together to fight cancer by enabling personalized treatments.

Navignostics specializes in analyzing tumor samples to identify the best way to target each cancerous growth, allowing clinicians to find the right therapy for each patient and supporting researchers in developing new drugs. They combine highly multiplex protein imaging with advanced data analytics for their spatial single-cell proteomics approach, validated through over a decade of translational and clinical research.

The company focuses on diagnostics to help clinicians identify optimal therapy from a single tumor tissue section, and research to support translational research, biomarker identification, and drug developers in recognizing patients that can benefit from novel treatments.